AbstractMer receptor tyrosine kinase is a promising novel cancer therapeutic target in many human cancers, because abnormal activation of Mer has been implicated in survival signaling and chemoresistance. 3D-QSAR analyses based on alignment independent descriptors were performed on a series of 81 Mer specific tyrosine kinase inhibitors. The fractional factorial design (FFD) and the enhanced replacement method (ERM) were applied and tested as variable selection algorithms for the selection of optimal subsets of molecular descriptors from a much greater pool of such regression variables. The data set was split into 65 molecules as the training set and 16 compounds as the test set. All descriptors were generated by using the GRid INdependent d...
<div><p>Checkpoint kinase 1 (Chk1) is a promising target for the design of novel anticancer agents. ...
Bladder cancer is the common reason for mortality worldwide, and its increasing rate announces as a ...
In an effort to develop a quantitative ligand-binding model for the receptor tyrosine kinases, a pha...
AbstractMer receptor tyrosine kinase is a promising novel cancer therapeutic target in many human ca...
Tyrosine kinases constitute an eligible class of target for novel drug discovery. They resulted ofte...
The p38 signaling cascade has emerged as an attractive target for the design of novel...
Quality QSAR: A combination of docking calculations and a statistical approach toward Abl inhibitors...
Quality QSAR: A combination of docking calculations and a statistical approach toward Abl inhibitors...
Quality QSAR: A combination of docking calculations and a statistical approach toward Abl inhibitors...
A therapeutic rationale is proposed by selectively targeting tyrosine kinase 2 (TYK 2) to obtain pot...
Purpose: Receptor tyrosine kinase (RTK) inhibitors are widely used pharmaceuticals in cancer therapy...
AbstractProtein kinases are essential components of various signaling pathways and represent attract...
B-Raf kinase is an important target in treatment of cancers. In order to design and find potent B-Ra...
In an effort to develop a quantitative ligand-binding model for the receptor tyrosine kinases, a pha...
B-Raf kinase is an important target in treatment of cancers. In order to design and find potent B-Ra...
<div><p>Checkpoint kinase 1 (Chk1) is a promising target for the design of novel anticancer agents. ...
Bladder cancer is the common reason for mortality worldwide, and its increasing rate announces as a ...
In an effort to develop a quantitative ligand-binding model for the receptor tyrosine kinases, a pha...
AbstractMer receptor tyrosine kinase is a promising novel cancer therapeutic target in many human ca...
Tyrosine kinases constitute an eligible class of target for novel drug discovery. They resulted ofte...
The p38 signaling cascade has emerged as an attractive target for the design of novel...
Quality QSAR: A combination of docking calculations and a statistical approach toward Abl inhibitors...
Quality QSAR: A combination of docking calculations and a statistical approach toward Abl inhibitors...
Quality QSAR: A combination of docking calculations and a statistical approach toward Abl inhibitors...
A therapeutic rationale is proposed by selectively targeting tyrosine kinase 2 (TYK 2) to obtain pot...
Purpose: Receptor tyrosine kinase (RTK) inhibitors are widely used pharmaceuticals in cancer therapy...
AbstractProtein kinases are essential components of various signaling pathways and represent attract...
B-Raf kinase is an important target in treatment of cancers. In order to design and find potent B-Ra...
In an effort to develop a quantitative ligand-binding model for the receptor tyrosine kinases, a pha...
B-Raf kinase is an important target in treatment of cancers. In order to design and find potent B-Ra...
<div><p>Checkpoint kinase 1 (Chk1) is a promising target for the design of novel anticancer agents. ...
Bladder cancer is the common reason for mortality worldwide, and its increasing rate announces as a ...
In an effort to develop a quantitative ligand-binding model for the receptor tyrosine kinases, a pha...